Cancer-associated thrombosis (including venous thromboembolism (VTE) and arterial
events) is highly consequential for patients with cancer and is associated with worsened …

Background Upper extremity deep vein thrombosis (UEDVT) accounts for~ 10% of all cases
of DVT. In the most widely referenced general review of DVT, the American Academy of …

Background Venous thromboembolism is a frequent complication of COVID-19 infection.
Less than 50% of pulmonary embolism (PE) is associated with the evidence of deep venous …

Background The natural history of patients with hematologic cancer and venous
thromboembolism (VTE) has not been consistently evaluated. We aimed to compare the …

Background For more than a decade, guidelines have recommended a limited 3 months of
anticoagulation for the treatment of provoked venous thromboembolism (VTE). How closely …

The term unusual site thrombosis refers to the occurrence of venous thromboembolism
outside of the lower limbs and the pulmonary arteries. Unusual site thrombosis can virtually …

La trombosis asociada al cáncer es una de las principales causas de morbimortalidad en
los pacientes oncológicos; tiene una incidencia de 13.9 por 1000 personas año …

2.3. 7.3. 1. ვიტამინ K ს ანტაგონისტები და ასპირინი გახანგრძლივებული
ანტიკოაგულაციის დროს. 2.3. 7.3. 2. პირდაპირი ორალური ანტიკოაგულანტების …

BACKGROUND: For more than a decade, guidelines have recommended a limited 3 months
of anticoagulation for the treatment of provoked venous thromboembolism (VTE). How …